Header Ads

Juno Therapeutics Stock Hits Jackpot


Juno Therapeutics stock hits jackpot  

Juno Therapeutics is a biopharmaceutical company founded in 2013 is ready for a takeover by Celgene Corp for about $9 billion.

The two companies said the deal agreed by both boards, is now ready to close in the first a quarter of 2018 and will give a huge boom to the companies wealth.

New Jersey-based company,  bluebird bio Inc and Agios Pharmaceuticals Inc summit, both of which are developing cancer treatments along with Juno Therapeutics.

Juno’s Therapeutics stock rose about 27 percent to $86.20 in New York before the markets opened today morning.Celgene is was sky high on cancer drugs after suffering a major setback last year that sent its market value tumbling. 

Celgene is now working with Seattle based Juno Therapeutics on new gene therapy that is designed to treat people with lymphoma disease.

Jefferies Stock analysts stated that potential acquisition is a  "smart move because the overtake enables Celgene to integrate Juno's entire cell therapy technology bring all at single place"

It is predicted that new treatments will help Celgene reduce its reliance on Revlimid, it's the top-selling cancer drug that includes more than 60 percent of its revenue.

The transaction is expected to close in the first quarter. J.P. Morgan Securities LLC is advising Celgene and Morgan Stanley & Co. 

Novartis and Gilead Sciences already received the first two approvals of the CART for other types of cancer.Celgene stated that latest acquisition is expected to add to its 2020 target net revenue 
incrementally, but will not affect adjusted earnings forecast of more than $13 per share.

So what are you waiting for, it's time to buy Juno Therapeutics stock now. Thanks for reading and have a nice day.

No comments

Powered by Blogger.